Bustos, M. A., et al. Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma. J Clin Oncol 39, 2021 (suppl 15; abstr e16577); DOI: 10.1200/JCO.2021.39.15_suppl.e16577
Mens, M. et al. Circulatory MicroRNAs as Potential Biomarkers for Stroke Risk. Stroke. 2021 FEB 10 . https://doi.org/10.1161/STROKEAHA.120.031543
Bustos, M. A., et al. Identification of cell-free microRNA signatures in pre-operative plasma from breast cancer patients. Cancer Res February 15 2021 (81) (4 Supplement) PS2-17; DOI: 10.1158/1538-7445.SABCS20-PS2-17
Wu., J. et al. Biological Age in Healthy Elderly Predicts Dementia in the Absence of a Brain Marker. Research Square. DEC 11.2020 DOI: https://doi.org/10.21203/rs.3.rs-119310/v1. Preprint
Moura, D. S., et al. Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study. J Clin Oncol 38: 2020 (suppl; abstr 11546). DOI: 10.1200/JCO.2020.38.15_suppl.11546
Download jpg 6.0MB
View External Link
Desai, J., et al. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e15258).
Buschur, K., et al. Vaping-Associated Variation in MicroRNA Expression in Circulating Extraceullular Vesicles. American Journal of Respitory and Critical Care Medicine AJRCCM (2020) Abstract A29.
Danza, J., et al. HLA-E Expression Predicts Progression, Therapeutic Response and Overall Survival in Patients with Bladder Cancer. The Journal of Urology 2020 APR: 203(4) e228-e229.
Hierro, C., et al. FGFR1-4 High mRNA Expression (mRNAh) as Predictive Biomarker for FGFR Inhibitors in Breast Cancer (BC). Annals of Oncology 2020 MAR:31(S1),S8-S9., Abstract 29P.
Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)
Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.
Gargiuli, C., et al. Comparative study of RT-qPCR-and NGS-based platforms for circulating human microRNA biomarker detection. Molecular Analysis for Personalised Therapy 2019;30(7).
Page last updated May 22, 2023